Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section , Translational Addiction Medicine Branch , National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism , National Institutes of Health , Baltimore and Bethesda , Maryland , USA.
Medication Development Program , National Institute on Drug Abuse Intramural Research Program , National Institutes of Health , Baltimore , Maryland , USA.
Hepatology. 2023 Mar 1;77(3):1006-1021. doi: 10.1002/hep.32531. Epub 2023 Feb 17.
Rising rates of alcohol use disorder (AUD) combined with increases in alcohol-related liver disease (ALD) and other liver disease have resulted in the need to develop alcohol management strategies at all levels of patient care. For those with pre-existing liver disease, whether ALD or others, attention to alcohol use treatment and abstinence becomes critical to avoiding worsening liver-related consequences. Modalities to help patients reduce or stop alcohol include screening/brief intervention/referral to treatment, various therapeutic modalities including cognitive behavioral therapy, motivational enhancement therapy and 12-step facilitation, and alcohol relapse prevention medications. Harm reduction approaches versus total abstinence may be considered, but for those with existing ALD, particularly advanced ALD (cirrhosis or acute alcoholic hepatitis), total abstinence from alcohol is the recommendation, given clear data that ongoing alcohol use worsens mortality and liver-related morbidity. For certain populations, alcohol cessation is even more critically important. For those with hepatitis C or NAFLD, alcohol use accelerates negative liver-related outcomes. In women, alcohol use accelerates liver damage and results in worsened liver-related mortality. Efforts to integrate AUD and liver disease care are urgently needed and can occur at several levels, with establishment of multidisciplinary ALD clinics for fully integrated co-management as an important goal.
酒精使用障碍(AUD)的发病率不断上升,加上与酒精相关的肝病(ALD)和其他肝病的增加,导致需要在患者护理的各个层面制定酒精管理策略。对于那些已经存在肝脏疾病的患者,无论是 ALD 还是其他疾病,关注酒精使用治疗和戒除酒精对于避免肝脏相关后果恶化至关重要。帮助患者减少或停止饮酒的方法包括筛查/简短干预/转介治疗、包括认知行为疗法、动机增强疗法和 12 步促进在内的各种治疗方法,以及酒精戒断预防药物。可以考虑减少危害的方法与完全戒断,但对于已经存在 ALD 的患者,特别是晚期 ALD(肝硬化或急性酒精性肝炎),由于持续饮酒会导致死亡率和肝脏相关发病率恶化,因此建议完全戒断酒精。对于某些人群,戒酒更为重要。对于患有丙型肝炎或非酒精性脂肪性肝病的患者,饮酒会加速肝脏的负面变化。对于女性,饮酒会加速肝脏损伤并导致肝脏相关死亡率恶化。迫切需要整合 AUD 和肝病护理,这可以在几个层面上进行,建立多学科 ALD 诊所,进行全面的综合管理是一个重要目标。